Monday, May 10, 2021
Home > Articles > Biotech firm Atai raises another $157m

Biotech firm Atai raises another $157m


Berlin-headquartered biotech firm Atai Life Sciences, which specialises in psychedelic treatments for mental health disorders, has raised $157m amid the global race to commercialise psychedelics. 

The company’s Series D raise follows a $125m funding round in November last year and comes as it’s rumoured to be preparing an IPO. The valuation on Wednesday was not disclosed, but Bloomberg reported that it was $2bn.

“We continue on our mission challenging the current way mental health conditions are treated,” said Florian Brand, CEO and cofounder of Atai. “We have become better equipped than ever to accelerate the development of more efficacious treatments.”

Atai’s investors

The investors in Atai’s $157m Series D include:

  • Thiel Capital 
  • Apeirion Investment Group — the family office of Atai’s founder, Christian Angermayer. Sifted chatted with Angermayer about Atai and his other investments earlier this year. 
  • Woodline Partners LP
  • Fearless Ventures
  • Falcon Edge Capital
  • Pura Vida Pro LLC
  • Catalio Capital Management 
  • Subversive Capital, Michael Auerbach
  • Highline Capital 
Share Button
Pls SUBSCRIBE below to our Youtube channel and mailing list to get fresh updates on money making and inspiring videos and articles.
READ  You Can Earn Up To N50k-N100k Daily From Giftalworld
Akinola Olusegun is a blogger and publisher of this blog, You can also check out his other blogs : (videos & news), (e-commerce), (news) among others. Follow him via any or all of his social media pages to get fresh posts update.

Leave a Reply

Your email address will not be published. Required fields are marked *